<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363421">
  <stage>Registered</stage>
  <submitdate>11/01/2013</submitdate>
  <approvaldate>14/01/2013</approvaldate>
  <actrnumber>ACTRN12613000036718</actrnumber>
  <trial_identification>
    <studytitle>the effect of ondansetron on hypotension due to spinal anesthesia for caesarean section.</studytitle>
    <scientifictitle>spinal-induced hypotension reduction with ondansetron
in parturients undergoing caesarean section: A double-blind
randomised, controlled study.</scientifictitle>
    <utrn>U1111-1138-4350 </utrn>
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>hypotension induced by spinal anesthesia for caeserean section</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Other anaesthesiology</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Childbirth and postnatal care</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>4 mg ondansetron (4 milliliters) given intravenously, 5 minutes before spinal anesthesia (using 10 mg hyperbaric bupivacaine 0.5% plus 2.5 microgramm sufentanil)</interventions>
    <comparator>4 milliliters of saline solution given intravenously, 5 minutes before spinal anesthesia (using 10 mg hyperbaric bupivacaine 0.5% plus 2.5 microgramm sufentanil)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>diastolic blood pressure. </outcome>
      <timepoint>baseline time (before injection of ondonsetron or saline),at the end of spinal injection and every 5 minutes until end of surgey. 
non invasive blood pressure



</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>neonates pH</outcome>
      <timepoint>at delivery.

arterial blood gas from umbilical cord</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>heart rate</outcome>
      <timepoint>baseline time (before injection of ondonsetron or saline),at the end of spinal injection and every 5 minutes until end of surgey. 

electrocardioscope</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>maternal oxygen saturation
</outcome>
      <timepoint>at time of spinal injection and at 5-min intervals  until the end of surgery

pulse oxymetry</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Upper sensory levels

pinkprick and cold test
</outcome>
      <timepoint>5-min intervals from spinal injection to 10 minutes</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Nausea and vomiting and pruritis

spontaneous reporting, clinical manifestations (retching, vomiting or itching) and any request for antiemiting or antihistaminic medications </outcome>
      <timepoint>when occured until 2 days after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>systolic blood pressure</outcome>
      <timepoint>baseline time (before injection of ondonsetron or saline),at the end of spinal injection and every 5 minutes until end of surgey. 

non invasive blood pressure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>mean blood pressure</outcome>
      <timepoint>baseline time (before injection of ondonsetron or saline),at the end of spinal injection and every 5 minutes until end of surgey. 

non invasive blood pressure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>maternal lactates</outcome>
      <timepoint>basliene time (before injection of ondonsetron or saline) and  at cutaneous incision

arterial blood gas</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>apgar score</outcome>
      <timepoint>at 1,3,5 and 10 minutes after birth</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>parturients ,who were ASA physical status I, undergoing an elective caesarean section</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Parturients with contraindications to subarachnoid block
(patient refusal, unstable haemodynamics, coagulation
abnormality), history of hypersensitivity to ondansetron or local anaesthetic agents, hypertensive disorders of
pregnancy, cardiovascular insufficiency and parturients receiving selective serotonin reuptake inhibitors</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation was concealed by sealed opaque envelopes </concealment>
    <sequence>Simple randomisation using coin-tossing </sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/02/2013</anticipatedstartdate>
    <actualstartdate>5/02/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>23/10/2013</actualenddate>
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Tunisia</country>
      <state>TUNIS</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Tunisian Military Hospital</primarysponsorname>
    <primarysponsoraddress>20 Montfleury street; 1002 Tunis; TUNISIA</primarysponsoraddress>
    <primarysponsorcountry>Tunisia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Tunisian Military Hospital</fundingname>
      <fundingaddress>20 Montfleury street; 1002 Tunis; TUNISIA</fundingaddress>
      <fundingcountry>Tunisia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>spinal-induced hypotension results primarily from decreased vascular resistance secondary to a relative parasympathetic dominance, increased baroreceptor activity, or induction of the Bezold Jarisch Reflex (BJR). several animal studies
suggest that 5-HT (serotonin) may be an important factor
associated inducing the BJR.
We hypothesized that spinal-induced
hypotension and bradycardia could be minimized
with the use of intravenous ondansetron, a 5-HT3 receptor
antagonist, in obstetric patients undergoing caesarean section.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Tunisian Military Hospital local ethic committee</ethicname>
      <ethicaddress>20 Montfleury street 1002 Tunis; TUNISIA</ethicaddress>
      <ethicapprovaldate>19/12/2012</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>14/12/2012</ethicsubmitdate>
      <ethiccountry>Tunisia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Trabelsi walid</name>
      <address>departement of anesthesia and intensive care unit, Tunisian Military Hospital, 20 Montfleury street 1002 Tunis; TUNISIA</address>
      <phone>+216 24091983</phone>
      <fax />
      <email>walid_trabelsi2009@yahoo.fr</email>
      <country>Tunisia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Trabelsi walid</name>
      <address>departement of anesthesia and intensive care unit, Tunisian Military Hospital, 20 Montfleury street 1002 Tunis; TUNISIA</address>
      <phone>+216 24091983</phone>
      <fax />
      <email>walid_trabelsi2009@yahoo.fr</email>
      <country>Tunisia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Trabelsi walid</name>
      <address>departement of anesthesia and intensive care unit, Tunisian Military Hospital, 20 Montfleury street 1002 Tunis; TUNISIA</address>
      <phone>+216 24091983</phone>
      <fax />
      <email>walid_trabelsi2009@yahoo.fr</email>
      <country>Tunisia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>